Interactions of Human Insulin with Deae-Dextran

DEAE-dextran hydrochloride behaviour in aqueous solution-The effect of ionic strength and concentration

DEAE-dextran hydrochloride is a positively charged biocompatible polyelectrolyte. Its behaviour in aqueous solutions - the changes in its colloidal characteristics and resulting conformation changes - were investigated using a combination of light scattering, densitometry and ultrasound spectrometry. The results indicated the formation of a voluminous, hydrated and coiled conformation of chains having average particle sizes in the range of units of microns at low ionic strength. This phenomenon was supported by an increase in DEAE-dextran hydrochloride concentration in the solution. The increase in ionic strength caused the shielding of DEAE-dextran hydrochloride charges on its chain, resulting in the destabilization of the conformation arrangement of the polyelectrolyte and the formation of denser, more compact and stiffer structures having smaller particle sizes. The proposed model of DEAE-dextran hydrochloride density in the studied environments (distilled water, NaCl solutions) showed the possibility of using a single equation model to calculate the overall density of the system.

Microencapsulation of human insulin DEAE-dextran complex and the complex in liposomes by the emulsion non-solvent addition method

Human insulin-DEAE (diethyl amino ethyl) dextran complex and human insulin DEAE-dextran complex in liposomes were encapsulated in cellulose acetate butyrate (CAB) microcapsules by the emulsion non-solvent addition method. The ratio of core-to-coat used was 1:1. The average diameters of the complex microcapsules and the complex liposome microcapsules were 239.5 +/- 77.5 and 182.9 +/- 52.2 microns respectively. In vitro dissolution studies of both types of microcapsules in simulated intestinal fluid at pH 7.2 showed a sustained release of the complex and the complex liposome microcapsules with t50 = 1.5 h and 4 h respectively. This study can be applied to the further development of oral formulations of human insulin liposomes for diabetic treatment.